Biotechnology company with real estate assets focusing on cellular therapies and diagnostics.
Avalon GloboCare Corp., along with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. In addition to its real estate operations, the company offers a range of medical-related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and management services in immunotherapy and second opinion/referral services.
Avalon GloboCare Corp. is advancing its leading candidates in the field of cell therapy, with AVA-001, an anti-CD19 CAR-T therapy that has completed its first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia. Another promising candidate, AVA-011, has completed pre-clinical laboratory studies and is undergoing IND-enabling process development to generate cGMP-grade AVA-011 CAR-T cells. The company is also developing an RNA-based FASH-CARTM cell therapy platform.
In its efforts to innovate in medical technology, Avalon GloboCare is developing the Avalon clinical-grade tissue-specific exosome (ACTEX) and is collaborating with the Massachusetts Institute of Technology (MIT) to utilize QTY-code protein design technology for therapeutic and diagnostic purposes. This includes the development of a hemofiltration device to treat Cytokine Storm. Additionally, the company is working with Arbele Limited to co-develop next-generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities.
Further expanding its research and development initiatives, Avalon GloboCare has a strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine for SARS-CoV-2 and COVID-19, which could be administered intranasally or orally. The company is also developing Avalon Cell and Avalon Rehab, promoting standardization within the exosome industry. Avalon GloboCare Corp. is headquartered in Freehold, New Jersey.